{"id":"W3194203975","doi":"10.1182/blood.2021012082","title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Oncology; National Cancer Institute; National Institute for Health and Care Research","keywords":"Ponatinib; Medicine; Internal medicine; Clinical endpoint; Adverse effect; Myeloid leukemia; Cohort; Confidence interval; Oncology; Nilotinib; Clinical trial; Imatinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003822922,0.000673794,0.003029006,0.0002958809,0.0001933902,0.0001704068,0.0006083202,0.0004147318,0.001098157],"category_scores_gemma":[0.002465391,0.0005961304,0.0004942097,0.0009388786,0.0002437796,0.0003027122,0.0006583408,0.001302691,0.0002260914],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.004784893,"about_ca_system_score_gemma":0.01526273,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004117774,"about_ca_topic_score_gemma":0.0007040055,"domain_scores_codex":[0.9926581,0.001369658,0.002503987,0.001542968,0.0008590441,0.001066291],"domain_scores_gemma":[0.9957597,0.001479406,0.0005168704,0.0015439,0.0002040813,0.00049599],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7782721,0.1210563,0.0008118137,0.0002831655,0.004162675,0.01800925,0.001129007,0.00001967023,0.004435549,0.0001641211,0.0007772642,0.07087912],"study_design_scores_gemma":[0.977348,0.01212729,0.0001435917,0.0004686805,0.002687031,0.000356309,0.0002993701,0.001973121,0.002153189,0.0000424514,0.001889998,0.0005109959],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9783043,0.00652893,0.00004331041,0.000374358,0.0008433384,0.01017622,0.00004474366,0.0001545343,0.003530272],"genre_scores_gemma":[0.9908096,0.000917343,0.001147859,0.0003532302,0.00224001,0.001498466,0.00031305,0.0001420538,0.002578458],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1990758,"threshold_uncertainty_score":0.999815,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08930478020376911,"score_gpt":0.4306504869785546,"score_spread":0.3413457067747855,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}